Education
About Us
Working with TipRanks
Follow Us
Conmed (CNMD)
NYSE:CNMD
CNMD Analyst Ratings
Moderate Buy
1 Buy
2 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
CNMD Stock 12 Month Forecast
Average Price Target
$53.50
▲(20.63% Upside)
| Highest Price Target$55.00 | Average Price Target$53.50 | Lowest Price Target$52.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Bank of America Securities
$52
Hold
17.25%
Upside
Reiterated
12/08/25
Conmed's Strategic Exit from Gastroenterology: Hold Rating Amid Portfolio Optimization and Financial AdjustmentsWe assume the cash payment is to offset profits CNMD is foregoing in 2026. We estimate the net after tax profit is likely somewhere around $20m and thus we estimate CNMD might have gotten about $15-20m of cash to exit the agreement a year early. A $20m buyback would add about $0.05 to CNMD’s EPS. There’s a benefit to Gore to have CNMD turn these products over in a friendly way and working with customers to ensure a smooth transition. Exit accretive to gross margins but dilutive to EPS in 2026 CNMD expects the exited gastroenterology product line revenues to be $90-$95m in 2025 (~$60m from Gore products and then shutting down another $30-35m in other GI related products) with gross margins of ~45%. In Jan’25, CNMD said GI revenues were expected to generate mid to high single digit growth over the mid-term.
Needham
―
Hold
―
Reiterated
12/05/25
Analysts Offer Insights on Healthcare Companies: CG Oncology, Inc. (NASDAQ: CGON) and Conmed (NYSE: CNMD)We also expect the exit to be accretive to CNMD's organic growth although CNMD did not quantify this. CNMD does not expect a material impact in 2025, and reaffirmed its financial guidance. We expect CNMD to provide more details on the exit and proceeds from the end of the distribution agreement on its 4Q25 earnings call. We lower our 2026E and 2027E estimates to account for the gastroenterology exit.
J.P. Morgan
$58→$52
Hold
17.25%
Upside
Reiterated
11/06/25
Piper Sandler
$68→$55
Buy
24.01%
Upside
Reiterated
11/06/25
Unknown Analyst
JefferiesNot Ranked
Jefferies
―
Hold
―
Reiterated
05/02/25
We maintain our Hold rating on CNMD.
Stifel Nicolaus
$55
Hold
24.01%
Upside
Reiterated
05/01/25
Wells Fargo
$70→$57
Hold
28.52%
Upside
Reiterated
04/30/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Bank of America Securities
$52
Hold
17.25%
Upside
Reiterated
12/08/25
Conmed's Strategic Exit from Gastroenterology: Hold Rating Amid Portfolio Optimization and Financial AdjustmentsWe assume the cash payment is to offset profits CNMD is foregoing in 2026. We estimate the net after tax profit is likely somewhere around $20m and thus we estimate CNMD might have gotten about $15-20m of cash to exit the agreement a year early. A $20m buyback would add about $0.05 to CNMD’s EPS. There’s a benefit to Gore to have CNMD turn these products over in a friendly way and working with customers to ensure a smooth transition. Exit accretive to gross margins but dilutive to EPS in 2026 CNMD expects the exited gastroenterology product line revenues to be $90-$95m in 2025 (~$60m from Gore products and then shutting down another $30-35m in other GI related products) with gross margins of ~45%. In Jan’25, CNMD said GI revenues were expected to generate mid to high single digit growth over the mid-term.
Needham
―
Hold
―
Reiterated
12/05/25
Analysts Offer Insights on Healthcare Companies: CG Oncology, Inc. (NASDAQ: CGON) and Conmed (NYSE: CNMD)We also expect the exit to be accretive to CNMD's organic growth although CNMD did not quantify this. CNMD does not expect a material impact in 2025, and reaffirmed its financial guidance. We expect CNMD to provide more details on the exit and proceeds from the end of the distribution agreement on its 4Q25 earnings call. We lower our 2026E and 2027E estimates to account for the gastroenterology exit.
J.P. Morgan
$58→$52
Hold
17.25%
Upside
Reiterated
11/06/25
Piper Sandler
$68→$55
Buy
24.01%
Upside
Reiterated
11/06/25
Unknown Analyst
JefferiesNot Ranked
Jefferies
―
Hold
―
Reiterated
05/02/25
We maintain our Hold rating on CNMD.
Stifel Nicolaus
$55
Hold
24.01%
Upside
Reiterated
05/01/25
Wells Fargo
$70→$57
Hold
28.52%
Upside
Reiterated
04/30/25
Best Analysts Covering Conmed
1 Month
xxx
Success Rate
6/20 ratings generated profit
Average Return
-1.65%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 30.00% of your transactions generating a profit, with an average return of -1.65% per trade.
3 Months
xxx
Success Rate
6/20 ratings generated profit
Average Return
-5.15%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 30.00% of your transactions generating a profit, with an average return of -5.15% per trade.
1 Year
Success Rate
4/20 ratings generated profit
Average Return
-18.38%
reiterated a buy rating last month
Copying Matthew O'Brien's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -18.38% per trade.
2 Years
xxx
Success Rate
0/20 ratings generated profit
Average Return
-35.38%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -35.38% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
CNMD Analyst Recommendation Trends
Rating
Aug 25
Sep 25
Oct 25
Nov 25
Dec 25
Strong Buy
0
0
0
0
0
Buy
11
14
13
8
3
Hold
1
1
0
3
6
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
12
15
13
11
9
Each month's total comprises the sum of three months' worth of ratings.
CNMD Financial Forecast
CNMD Stock Forecast FAQ
What is CNMD’s average 12-month price target, according to analysts?
Based on analyst ratings, Conmed’s 12-month average price target is 53.50.
What is CNMD’s upside potential, based on the analysts’ average price target?
Conmed has 20.63% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is CNMD a Buy, Sell or Hold?
Conmed has a consensus rating of Moderate Buy which is based on 1 buy ratings, 2 hold ratings and 0 sell ratings.
What is Conmed’s price target?
The average price target for Conmed is 53.50. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $55.00 ,the lowest forecast is $52.00. The average price target represents 20.63% Increase from the current price of $44.35.
The highest analyst price target is $55.00 ,the lowest forecast is $52.00. The average price target represents 20.63% Increase from the current price of $44.35.
What do analysts say about Conmed?
Conmed’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 3 Wall Streets Analysts.
How can I buy shares of CNMD?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.